These results further contribute to the emerging interest in RSKs and/or PDCD4 as promising therapeutic targets for the treatment of TNBC and other cancers with up-regulated MAPK pathway such as lung, colorectal, pancreatic and melanoma. This evidence concerns the gene PDCD4 and cancer.